Sign up to save your podcasts
Or
Share Protective role of neonatal CMV infection in B-ALL; GVHD targets organoid-forming bile duct stem cells; seven-year outcomes for venetoclax-ibrutinib therapy in MCL
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Protective role of neonatal CMV infection in B-ALL; GVHD targets organoid-forming bile duct stem cells; seven-year outcomes for venetoclax-ibrutinib therapy in MCL
In this week's episode we'll learn how cytomegalovirus infection early in life depletes preleukemic cells in a mouse model of B-cell acute lymphoblastic leukemia. After that we'll discuss new research, where GVHD targets organoid-forming bile duct stem cells in a TGF-beta-dependent manner. Conversely, a TGF-beta inhibitor protects these stem cells against GVHD and mitigates biliary dysfunction. Finally, we'll hear about the seven-year outcomes for venetoclax-ibrutinib in relapsed or refractory mantle cell lymphoma. In addition to long-term survival benefits, researchers report durable treatment-free remissions and effective retreatment in patients with MRD-negative complete responses.
Featured Articles:
- Early-life infection depletes preleukemic cells in a mouse model of hyperdiploid B-cell acute lymphoblastic
leukemia - GVHD targets organoid-forming bile duct stem cells in a TGF-β–dependent manner
- Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and
treatment-free remissions
View all episodes
By American Society of Hematology
4.1
4949 ratings
In this week's episode we'll learn how cytomegalovirus infection early in life depletes preleukemic cells in a mouse model of B-cell acute lymphoblastic leukemia. After that we'll discuss new research, where GVHD targets organoid-forming bile duct stem cells in a TGF-beta-dependent manner. Conversely, a TGF-beta inhibitor protects these stem cells against GVHD and mitigates biliary dysfunction. Finally, we'll hear about the seven-year outcomes for venetoclax-ibrutinib in relapsed or refractory mantle cell lymphoma. In addition to long-term survival benefits, researchers report durable treatment-free remissions and effective retreatment in patients with MRD-negative complete responses.
Featured Articles:
- Early-life infection depletes preleukemic cells in a mouse model of hyperdiploid B-cell acute lymphoblastic
leukemia - GVHD targets organoid-forming bile duct stem cells in a TGF-β–dependent manner
- Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and
treatment-free remissions
More shows like Blood Podcast
View all
TED Talks Daily
11,147 Listeners
JAMA Editors' Summary
140 Listeners
NEJM This Week
318 Listeners
JAMA Clinical Reviews
499 Listeners
Hematologic Oncology Update
75 Listeners
The Hematologist
26 Listeners
Core IM | Internal Medicine Podcast
1,157 Listeners
VJHemOnc Podcast
2 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
363 Listeners
The Curious Clinicians
373 Listeners
EHA Unplugged
1 Listeners
Blood Cancer Talks
48 Listeners
Two Onc Docs
190 Listeners
WolverHeme Happy Hour
30 Listeners
HemeTalks: Conversations in Hematology Education
4 Listeners